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Abstract
Alzheimer disease (AD) is a chronic neurodegenerative disease that is characterized by progressive
memory loss. Pathological markers of AD include neurofibrillary tangles, accumulation of amyloid-
β plaques, neuronal loss, and inflammation. The exact events that lead to the neuronal dysfunction
and loss are not completely understood. However, pro-inflammatory cytokines, such as
interleukin-1β, interleukin-6, and tumor necrosis factor α, are increased in AD, along with gene
expression of major histocompatibility complex (MHC) class II molecules and macrophage
migration inhibitory factor (MIF). MHC class II molecules are found in microglia of the brain, while
MIF is found in both microglia and neurons of the hypothalamus, hippocampus, and cortex. MIF is
not only a lymphocyte mediator but also a pituitary factor with endocrine properties and can
mediate phosphorylation of the extracellular signal-regulated kinase-1/2 MAP kinases pathway. In
this study, we looked at CD74, an integral membrane protein that acts as both a chaperone for
MHC class II molecules as well as a receptor binding site for MIF. CD74 was recently found to be
increased in microglia in AD cases compared to age-matched controls, but has not been reported
in neurons. In our analysis, immunohistochemistry revealed a significant increase in CD74 primarily
in neurofibrillary tangles, amyloid-β plaques, and microglia. This is the first finding to our knowledge
that CD74 is increased in neurons of AD cases compared to age-matched control cases.
Background
Alzheimer disease (AD) is a chronic neurodegenerative
disease that is pathologically characterized by neurofibril-
lary tangles (NFT), accumulation of amyloid-β (Aβ), and
increased inflammatory markers. However, many lines of
evidence suggest that mitogenic signaling, sex steroids,
oxidative stress and inflammation may also play a role in
the pathogenesis of the disease [1-3]. Increased inflamma-
tion has been associated with cognitive decline in AD.
Pro-inflammatory markers, such as interleukin-1β (IL-
1β), interleukin-6 (IL-6), and tumor necrosis factor α
(TNFα) are not only increased in AD patients, but also
increase Aβ [4,5]. The accumulation of Aβ then induces a
pro-inflammatory response, continuing the cycle.
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Recently, Parachikova and colleagues [6] found that there
was increased gene expression of the inflammatory mole-
cule, major histocompatibility complex (MHC) II in the
hippocampus of AD cases with mild/moderate dementia.
MHC class II was found primarily in the microglia and the
increase in MHC class II was correlated with cognitive
decline based on the mini-mental state exam (MMSE)
score. MHC class II is responsible for displaying degraded
foreign proteins to the cell surface for the recognition by
CD4+ T lymphocytes. CD74, also known as the invariant
chain, is known for its role in chaperoning the MHC class
II molecules from the endoplasmic reticulum to the cell
surface. CD74 blocks the peptide-binding site of MHC
class II molecules during transportation from the ER to
the cell surface [7].
Interestingly CD74 also mediates binding of the extracel-
lular pro-inflammatory cytokine macrophage migration
inhibitory factor (MIF) [8]. MIF is released in response to
stress or an inflammatory response. MIF down-regulates
the immunosuppressive effects of glucocorticoids and has
been found to increase in the brain and cerebrospinal
fluid in response to lipopolysaccharide [9]. Furthermore,
MIF can be induced to form amyloid fibrils and can bind
to Aβ [10,11]. The role of CD74 as an MHC class II chap-
erone and as a receptor for MIF, both of which contribute
to the pathology of AD, lead us to believe that CD74 may
play an important role in AD. Yoshiyama determined that
CD74 is increased in microglia of AD patients by means
of immunohistochemistry, but did not examine neuronal
CD74 [12]. Increased MIF mRNA was found in AD
patients in neurons [13]. Therefore, the aim of this study
is to determine if CD74 is altered in AD patients in both
the microglia and neurons.
Results
Immunocytochemistry
CD74 immunocytochemistry demonstrated labeling of
microglial processes within the gray matter of the hippoc-
ampal pyramidal cell layer and the subiculum, and was
most notable within microglial processes in and around
senile (neuritic and cored) plaques. This finding is overall
consistent with the literature on CD74 in AD brains. In
addition, however, we noted strong immunolabeling of
pyramidal neurons, both diffusely within the cytoplasm
of pathologically normal neurons, as well as co-labeling
of neurofibrillary pathology; in particular, neurofibrillary
tangles, neuropil threads, and dystrophic neurites within
neuritic senile plaques also showed strong immunoreac-
tivity in a distribution similar to phospho-tau immunore-
activity. Labeling of amyloid plaque cores per se and
diffuse plaques was not identified, nor was labeling of
blood vessels affected by cerebral amyloid angiopathy. No
labeling of granulovacuolar degeneration or Hirano bod-
ies was seen. No significant immunolabeling of macroglia
(astrocytes, oligodendrocytes) was present. Control tissue
showed no immunolabeling, either of neurons, macro-
glia, or microglia (Figure 1A,B).
Immunoblotting
Immunoblot of brain homogenates prepared from AD
and control hippocampus demonstrated protein bands at
Immunohistochemistry with the antibody to CD74 in AD (A) and control (B) hippocampus Figure 1
Immunohistochemistry with the antibody to CD74 in AD (A) and control (B) hippocampus. CD74 strongly 
stained neurofibrillary tangles (arrows), amyloid-β plaques (*) and microglia (inset) in the AD cases (n = 6), but not in controls 
(n = 6). Scale Bar = 50 μm.Molecular Neurodegeneration 2008, 3:13 http://www.molecularneurodegeneration.com/content/3/1/13
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approximately 30–37 kDa, consistent with reported
CD74 isoforms (Figure 2A). Statistical analysis of the 30
kDa band showed a significantly higher level of CD74 in
AD compared to control (p =< 0.01) (Figure 2C).
Discussion
AD is the most common neurodegenerative disorder, but
the cause of AD is still unknown. Pro-inflammatory mark-
ers IL-1β, IL-6, and TNFα are increased in AD patients as
well as the anti-inflammatory marker IL-10 [4,5].
Increases in two additional inflammatory markers, MIF
and MHC class II recently have been found in AD cases
compared to age-matched controls [6,8].
Immunohistochemistry results (Figure 1A,B) reveal that
the MIF receptor CD74 is increased in NFTs and microglia
of AD patients compared to age-matched controls. To our
knowledge this is the first study to find increased CD74
expression in neurons. Immunoblot analyses confirmed
our findings from the immunohistochemistry data in that
CD74 was expressed at the correct molecular weight in
both AD and control brains (Figure 2). Overall there was
a significant increase in CD74 in AD compared to control
cases, which may be related to the disease stage, with two
AD cases being more severe than the others and likely con-
taining more CD74-containing neurofibrillary pathology.
Additional cases will need to be analyized to confirm this.
Insoluble fragments were found at the top of the blot,
which may be due to the insoluble paired helical fila-
ments that compose NFTs [14]. This study is consistent
with previous findings that CD74 is increased in the
microglia of AD brain, but sheds light that CD74 is impor-
tant in NFTs as well.
The fact that CD74 is an extracellular surface receptor for
MIF was only recently discovered [8]. MIF has been found
in neurons of the hippocampus, hypothalamus, and cor-
tex and is often increased in AD patients compared to con-
trols [10]. CD74 is a high affinity binding protein for MIF
and is necessary for MIF-induced activation of the extra-
cellular-regulated-kinase (ERK) 1/2 MAP kinase cascade,
cell proliferation, and prostaglandin E2 (PGE2) produc-
tion [8]. In this regard, it is of interest to note that the ERK
pathway is activated in AD [14-17] and elevated levels of
PGE2 in AD are likely involved in Aβ production [18,19].
CD74 is mainly known as an MHC class II chaperone,
which allows the MHC class II molecules to leave the
endoplasmic reticulum and prevents binding of other
proteins to the MHC II molecule. Stimulation of CD74
leads to NFκB activation, entry of CD74 stimulated cells
into the S phase, elevation of the DNA synthesis, cell divi-
sion, and leads to cell proliferation and survival [20,21].
There is very little information on the role of CD74 in
neurodegenerative diseases. Yoshiyama and colleagues
[12] did determine that CD74 was increased in only rest-
ing or mildly active microglia of AD patients. Expression
of pro-Cathespin L, which is responsible for the degrada-
tion of CD74, was highly expressed in fully activated
microglia, but not in resting or mildly active microglia.
Therefore, in future studies, we will determine if increased
CD74 in NFTs is due to a dysregulation of Cathsepin L
[12].
NFTs are a hallmark characteristic of AD pathology and
are a result of tau accumulation. Oxidative stress and acti-
vation of cell cycle regulators are associated with NFT for-
mation [22,23]. Tau and neurofilament proteins contain
a high content of lysine-serine-proline (KSP) domains,
which makes them uniquely adapted to oxidative attack.
Oxidative stress through the activation of the MAP kinase
pathways leads to tau phosphorylation [24]. CD74 also
increases in response to oxidation and when stimulated
by MIF induces phosphorylation of ERK1/2 [8].
The cell cycle hypothesis of AD states that cell cycle dis-
ruptions occur in AD and that activation of cell cycle reg-
ulators precedes the formation of NFTs [25]. Furthermore,
markers from each phase of the cell cycle have been
accounted for in degenerating neurons, which has led
some to hypothesize that cells may re-enter the cell cycle
CD74 protein levels were assessed by Western blotting in  four AD cases (lanes 5–8) and four controls (lanes 1–4) Figure 2
CD74 protein levels were assessed by Western blot-
ting in four AD cases (lanes 5–8) and four controls 
(lanes 1–4). (A) Western blot for CD74. (B) Actin. The rel-
ative quantification and statistical analysis shows significantly 
higher (p =< 0.01) levels of CD74 in AD verses control brain 
(C).Molecular Neurodegeneration 2008, 3:13 http://www.molecularneurodegeneration.com/content/3/1/13
Page 4 of 5
(page number not for citation purposes)
through to the S phase, but for unknown reasons abort
somatic division leading to degeneration of the neuron.
CD74 regulates cell entry to the S phase in B cells. Cyclin
E is expressed on initiation of the S-phase and is upregu-
lated following CD74 stimulation [21]. Whether there is a
connection between CD74 activation and disruption of
the cell cycle in degenerating neurons is unknown, but
may be an indication as to why CD74 is found in NFTs. In
conclusion, CD74 is increased in microglia and neurons
in AD patients. NFTs had the greatest increase in CD74,
while microglia CD74 was only minimally increased. Our
results are the first to find an increase of CD74 in NFTs.
The mechanism and importance of CD74 in neurons has
yet to be elucidated and further studies need to be con-
ducted.
Methods
Immunocytochemistry
Postmortem hippocampal tissue from six confirmed AD
patients (ages 87–67) and six aged matched control
patients (ages 86–43) were fixed in methacarn (methanol-
chloroform-acetic acid; 6:3:1) overnight at 4°C, dehy-
drated in ascending ethanol and embedded in paraffin.
Six micron sections were cut and placed on plus coated
slides (Fisher Scientific, 25 × 75 × 1.0 mm). Sections were
then deparaffinized in xylene and hydrated through
decending ethanol. Endogenous peroxidase was
quenched with 3% hydrogen peroxide/methanol. Non-
specific binding sites were blocked with 10% normal goat
serum in TBS (150 mM Tris-buffered Saline, pH 7.6) fol-
lowed by incubation in the primary antibody, CD74
(1:100, Santa Cruz). The sections were stained with the
peroxidase anti-peroxidase method [26] with 3,3-diami-
nobenzidine (DAB) as the co-substrate as previously
described.
Immunoblotting
Poly-acrylamide gel electrophoresis was performed on
hippocampal and frontal cortex tissue from four AD and
four control cases. Samples were homogenized in TBS and
10 μg of protein was loaded per lane in Kelly's sample
buffer. Proteins were resolved on 10% SDS-PAGE gels and
transferred to Immobilon-P, PVDF membrane (Millipore
Corp., Billerica, MA). Membrane was probed with CD74
after non-specific binding sites were blocked with 10%
non-fat milk in TBS, followed by HRP linked secondary
(ICN). Proteins were detected with immobilon western
chemiluminescent HRP substrate (Millipore Corp., Biller-
ica, MA). The membrane was stripped with stripping rea-
gent and re-probed with actin as an internal loading
control.
Statistical Analysis
Densitometric analysis was performed with UN-SCAN-IT
gel 6.1 software (Silk Scientific; Oren, UT). Significance
was determined with the student t-Test.
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